Sunshine Biopharma Announces Successful Completion of Preclinical Studies for Adva-27a, the Company's Lead Anti-Cancer Compound

Montreal, November 16 (ots/PRNewswire) -

Sunshine Biopharma Inc. a development stage pharmaceutical
company focused on the research, development and commercialization of
drugs for the treatment of various forms of cancer, today announced
that it has successfully completed the preclinical studies for
Adva-27a, the Company's lead oncology drug candidate. Adva-27a was
found to have unique pharmaceutical properties of substantial
clinical interest. In summary, the results to date have shown that:

- Adva-27a is 16-times more effective at killing multidrug
resistant breast cancer cells than Etoposide, the drug currently in use.
- Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible
for making cancer cells resistant to anti-tumor drugs.
- Adva-27a has excellent clearance time (half-life = 54 minutes)
as indicated by human microsomes stability studies.
- Adva-27a clearance is independent of Cytochrome P450, a
mechanism that is less likely to produce toxic intermediates.
- Adva-27a is an excellent inhibitor of Topoisomerase II with an
IC50 of only 13.7 micromolar.
- Adva-27a has shown excellent pharmacokinetics profile as
indicated by studies done in rats.
- Adva-27a's initial indication will be multidrug resistant breast
cancer for which there are little or no treatment options.

"We are now ready to move to the next stage in our Adva-27a drug
development program," said Dr. Steve N. Slilaty, President and CEO of
Sunshine Biopharma. "In this stage we will conduct GMP manufacturing
of Adva-27a and then use the material to perform the so-called
IND-enabling studies, following which we will file our IND
Application and proceed to doing Phase I clinical trials," he added.
Dr. Slilaty also stated, "We are delighted to have completed this
milestone and are looking forward to the challenges ahead leading to
our ultimate goal of improving the quality of life for cancer
sufferers."

Safe Harbor Forward-Looking Statements

To the extent that statements in this press release are not
strictly historical, including statements as to revenue projections,
business strategy, outlook, objectives, future milestones, plans,
intentions, goals, future financial conditions, future collaboration
agreements, the success of the Company's development, events
conditioned on stockholder or other approval, or otherwise as to
future events, such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements
contained in this release are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the statements made.

For further information:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: +1-514-814-0464
camille.sebaaly@sunshinebiopharma.com

http://www.sunshinebiopharma.com

ots Originaltext: Sunshine Biopharma Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
.